Dr. Kubal completed his hematology/oncology fellowship at the University of South Florida at Moffitt Cancer Center, completing an MBA concurrently at the University of South Florida. Dr. Kubal's research and clinical interests are in myeloid malignancies with a particular focus in acute leukemias. In addition to his clinical efforts, Dr. Kubal serves as the medical director of process excellence and is focused on continuous improvement of the patient experience. Dr. Kubal will serve as Senior Medical Director of Moffitt at Wesley Chapel, and will serve full time at the Wesley Chapel campus.
Education & Training
Moffitt Cancer Center/University of South Florida - Hematology/Oncology
Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
Mason NT, Burkett JM, Nelson RS, Pow-Sang JM, Gatenby RA, Kubal T, Peabody JW, Letson GD, McLeod HL, Zhang J. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. Am Health Drug Benefits. 2021 Mar.14(1):15-20. Pubmedid: 33841621. Pmcid: PMC8025923.
Li W, Richter KA, Tobon KA, McCarthy KT, Kubal TE. Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. J Oncol Pharm Pract. 2020 Oct. Pubmedid: 33092499.
Sugalski J, Franco T, Shulman LN, Cinar P, Bachman J, Crews JR, Olsen M, Schatz A, Kubal T. Creative Strategies Implemented During the Coronavirus Pandemic That Will Impact the Future of Cancer Care. J Natl Compr Canc Ne. 2020 Oct.1-5. Pubmedid: 33126204.
Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, McLeod HL, Greene JN. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clin Pharmacol Ther. 2020 Mar.107(3):563-570. Pubmedid: 31549389. Pmcid: PMC7018540.
Talati C, Frantz D, Lubas A, Salamanca C, Tobon K, Kubal T. How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective. Future Oncol. 2020 Mar.16(7):281-291. Pubmedid: 31985277.
Cinar P, Kubal T, Freifeld A, Mishra A, Shulman L, Bachman J, Fonseca R, Uronis H, Klemanski D, Slusser K, Lunning M, Liu C. Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. J Natl Compr Canc Ne. 2020 Apr.1-6. Pubmedid: 32294617.
Johnson D, Ouenes O, Letson D, de Belen E, Kubal T, Czarnecki C, Weems L, Box B, Paculdo D, Peabody J. A Direct Comparison of the Clinical Practice Patterns of Advanced Practice Providers and Doctors. Am J Med. 2019 Nov.132(11):e778-e785. Pubmedid: 31145882.
Sugalski JM, Kubal T, Mulkerin DL, Caires RL, Moore PJ, Fiorarancio Fahy R, Gordon JN, Augustyniak CZ, Szymanski GM, Olsen M, Frantz DK, Quinn MA, Kidd SK, Krause DM, Carlson RW, Stewart FM. National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers. J Oncol Pract. 2019 May.15(5):e458-e466. Pubmedid: 30964732.
Colonna S, Sweetenham J, Burgon TB, Buys SS, Lynch R, Au T, Johnson E, Kubal T, Paculdo D, Acelajado MC, Peabody JW. A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care. Clin Breast Cancer. 2019 Apr.19(2):e376-e384. Pubmedid: 30711440.
Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar.92(3):232-237. Pubmedid: 28006850.
Kubal T, Letson DG, Chiappori AA, Springett GM, Shimkhada R, Tamondong Lachica D, Peabody JW. Longitudinal cohort study to determine effectiveness of a novel simulated case and feedback system to improve clinical pathway adherence in breast, lung and GI cancers. BMJ Open. 2016 Sep.6(9):e012312. Pubmedid: 27625063. Pmcid: PMC5030551.
Kubal T, Peabody JW, Friedman E, Levine R, Pursell S, Letson DG. Using Vignettes to Measure and Encourage Adherence to Clinical Pathways in a Quality-Based Oncology Network: An Early Report on the Moffitt Oncology Network Initiative. Manag Care. 2015 Oct.24(10):56-64. Pubmedid: 26665718.
Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014 Oct.21(4):322-327. Pubmedid: 25310213.
Kubal T, Lancet JE. The thorny issue of relapsed acute myeloid leukemia. Curr Opin Hematol. 2013 Mar.20(2):100-106. Pubmedid: 23385612.
Kim R, Kubal T. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. Clin Colorectal Cancer. 2012 Jun.11(2):85-87. Pubmedid: 22169039.
Winokur RS, Kubal T, Liu D, Davis SF, Smith BN. Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy. Epilepsy Res. 2004 Feb.58(2-3):93-105. Pubmedid: 15120741.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub